Endometrial cancer: Not your grandmother's cancer.
Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the highest disease burden is reported in North America and Western Europe. Although the prognosis remains good for patients with are diagnosed with early stage EC, for those with recurrent or metastatic disease, the options are few, and the median overall survival is short. It is imperative to gain a greater understanding of all aspects of EC, limit its effect on scarce health care resources and, more importantly, prevent this cancer from significantly impacting future generations of women. An exciting new era of endometrial cancer research and clinical management has begun that incorporates biologically and clinically relevant genomic and clinicopathologic parameters. Continued collaborative research efforts and funding are essential if we are to advance our understanding of this disease and improve clinical outcomes. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2787-2798. © 2016 American Cancer Society.
Department of Gynecology and Obstetrics, Division Gynecologic Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Jessica N
JN
McAlpine
Kelly Gynecologic Oncology Service, Johns Hopkins School of Medicine, Baltimore, Maryland.
Sarah M
SM
Temkin
Division of Medical Oncology and Hematology, Faculty of Medicine, University of Toronto, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada.
Helen J
HJ
Mackay
D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000235:genetics; D005260:Female; D006801:Humans; D011379:Prognosis
DNA polymerase ε catalytic subunit (POLE) mutations; Lynch syndrome; The Cancer Genome Atlas (TCGA); clinical trials; endometrial cancer; genomics; molecular classification; obesity and lifestyle factors; targeted therapy